statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Law Offices of Frank R. Cruz Announces Investigation of Complete Solaria Inc. (CSLR) f/k/a Freedom Acquisition I Corporation (FACT) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Complete Solaria Inc. (CSLR) f/k/a Freedom Acquisition I Corporation (FACT) on Behalf of Investors The Law Offices of Frank R. Cruz...

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Complete Solaria Inc. (Complete Solaria or Company) (NASDAQ: CSLR) f/k/a Freedom Acquisition I...

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology drugs. Facet was formed through a spin-off of the biotechnology segment of PDL BioPharma, Inc., which was completed on December 18, 2008. It was subsequently acquired by [Abbott Labs](/organization/abbott-labs). The company is headquartered in Redwood City, California.  Its products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I/II clinical studies, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases; and TRU-016, a small modular immunopharmaceutical protein therapeutic in Phase I clinical studies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin's lymphoma, as well as autoimmune and inflammatory disease indications. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; and Trubion Pharmaceuticals, Inc. Facet Biotech Corporation also has license agreements with Abbott Laboratories, Inc.; Actinium Pharmaceuticals, Inc.; Genentech, Inc.; Ophthotech Corporation; Progenics Pharmaceuticals, Inc.; and Seattle Genetics, Inc.

Facet Biotech

Freedom Acquisition I Corp - Ordinary Shares - Class A

Volume	33,505.00
52-Wk High	$0.00
52-Wk Low	$0.00

FACT Freedom Acquisition I Corp - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals